CMS每年发起500美元的激励计划, 资助大麻制品, 这引发了批评, 因为它在经过验证药物上补贴非FDA批准的产品. CMS launched a $500 annual incentive to fund hemp-derived products, sparking criticism for subsidizing non-FDA-approved items over proven medicines.

在2026年4月1日,CMS发起了每年的500美元激励计划,允许医疗保险相关组织资助大麻制品. CMS launched a $500 annual incentive on April 1, 2026, allowing Medicare-connected organizations to fund hemp-derived products. 批评者认为,该计划通过在2018年农业法案下补贴非FDA批准的麻产品而创造了监管双重标准,同时排除科学验证的药物制剂. Critics argue this program creates a regulatory double standard by subsidizing non-FDA-approved hemp products under the 2018 Farm Bill, while excluding scientifically validated pharmaceutical medicines. 政策因在已证明的疗法上奖励法律漏洞而受到批评, 并对未来可能发生的法律变化引起了患者安全方面的担忧. The policy faces criticism for rewarding legal loopholes over proven therapies and raises concerns about patient safety amid potential future legal changes.